Fly News Breaks for March 3, 2015
JAZZ
Mar 3, 2015 | 12:24 EDT
Cantor Fitzgerald raised its price target for shares of Jazz Pharmaceuticals to $175 after the company resolved its FDA dispute on the risk mitigation and evaluation program for its narcolepsy drug, Xyrem. The firm believes Jazz can now extend Xyrem patent life to 2022-2024, up from its prior assumption of 2020. Cantor continues to find the stock fairly valued and keeps a Hold rating on Jazz.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ